DarioHealth Issues Shareholder Update: Multi-Condition Leadership in Momentum Driven Digital Health Market
DRIO(NASDAQ:DRIO) NEW YORK, Sept. 3, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today issued a shareholder update highlighting strategic progress, robust market tailwinds, and accelerating growth opportunities. The full...
DarioHealth Announces 20-to-1 Reverse Stock Split
DRIONEW YORK, Aug. 25, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced that a reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the "Common...
Litchfield Hills Initiates Coverage On DarioHealth with Buy Rating, Announces Price Target of $3
DRIODarioHealth Q1 Adj. EPS $(0.12), Inline, Sales $6.75M Miss $7.48M Estimate
DRIOA Preview Of DarioHealth's Earnings
DRIODarioHealth CFO Zvi Ben-David To Retire Effective May 15, Co. Appoints Chen Franco-Yehuda As Chief Financial Officer, Treasurer And Secretary
DRIODarioHealth Forms Strategic Partnership With Leading Benefit Administrator To Offer Cardiometabolic Solution Including GLP-1 Support Program To Employers
DRIOStifel Maintains Buy on DarioHealth, Lowers Price Target to $2
DRIODarioHealth FY 2024 GAAP EPS $0.61 Beats $(1.01) Estimate, Sales $27.040M Beat $26.821M Estimate
DRIODarioHealth Collaborates With Rula Health To Expand Access To Mental Health Support For Employers And Workforce
DRIODario Signs Healthcare Contract For AI-Powered Chronic Care, Enhances Employee Benefits; Demonstrates 2.3 A1C Reduction, 28-30% Mental Health Improvement; 15 New Client Signings Expected in 2025; Financial Terms Not Disclosed
DRIODarioHealth Collaborates With MediOrbis To Add Capabilities To GLP-1 Solution
DRIODario Expands Pharma Collaborations With Global Pharma To Further Direct-To-Consumer Efforts Using Dario's Refined Engagement And Navigation Technologies.
DRIOLooking Into DarioHealth's Return On Capital Employed
DRIOBenzinga Pro data, DarioHealth (NASDAQ:DRIO) reported Q2 sales of $6.18 million. Earnings fell to a loss of $18.03 million, resulting in a 13.27% decrease from last quarter.
